The European Commission (EC) has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.

(RTTNews) - Alnylam Pharmaceuticals, Inc. (ALNY) announced Monday that the European Commission or EC has granted approval for AMVUTTRA (vutrisiran) for the treatment of wild-type or hereditary ...

− First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of Wild-Type or Hereditary ATTR Amyloidosis with Cardiomyopathy – − Novel RNAi Mechanism Delivers ...

The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR ...

First and Only RNAi Therapeutic Approved by the European Commission for the Treatment of Wild-Type or Hereditary ATTR Amyloidosis with Cardiomyopathy - - Novel RNAi Mechanism Delivers Rapid ...

AMVUTTRA now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of ...

The Shimane Prefectural Government headquarters is seen in this file photo. (Mainichi/Kazuhisa Soneda) MATSUE -- Shimane Prefecture announced on June 6 that an error ...

“Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved ...

BridgeBio Pharma emphasizes the potential for serum TTR levels to serve as a prognostic biomarker in ATTR-CM, aiding in treatment decisions and patient care. The company, which specializes in ...

“These data reinforce the positive results from the HELIOS-B primary analysis and further demonstrate the beneficial effect of vutrisiran on mortality rates and CV health for patients with ATTR ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer.

for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Results were shared in an oral presentation on Sunday, May 18 at the 2025 Peripheral Nerve Society (PNS) Annual Meeting ...